Mavyret approved as 8-week treatment for hep C, compensated cirrhosis
(HealthDay)—Approval of Mavyret (glecaprevir and pibrentasvir) tablets has been expanded to eight-week treatment for treatment-naive patients aged 12 years and older with chronic hepatitis C virus (HCV) genotypes 1 through ...
Oct 1, 2019
0
2